Vertex Pharma (VRTX) Misses Q1 EPS by 20c; Increases 2016 KALYDECO Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Vertex Pharma (VRTX) Sees Red-to-Green Reversal Following EPS
April 28, 2016 10:27 AM EDTVertex Pharma (NASDAQ: VRTX) reverse sharply off morning lows following earning after the close, which were seen as lackluster.
Shares are currently up 1% after opening down 3.9%.
... MoreVertex (VRTX) PT, Estimates Cut at Baird
April 28, 2016 7:45 AM EDTBaird analyst Brian Skorney lowered his price target on Vertex (NASDAQ: VRTX) to $128.00 (from $144.00) and Orkambi estimates on weak qua but maintained an Outperform rating.
Skorney commented, "Orkambi sales came in well below expectations that had already been revised significantly downwards over the last... More
Goldman Sachs Downgrades Vertex (VRTX) to Neutral
April 28, 2016 7:16 AM EDTGoldman Sachs downgraded Vertex (NASDAQ: VRTX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $84.50 yesterday.
... More